GSK's earnings have been declining at an average annual rate of -5.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 1.8% per year. GSK's return on equity is 21.2%, and it has net margins of 8%.
Key information
-5.2%
Earnings growth rate
-5.8%
EPS growth rate
Pharmaceuticals Industry Growth
7.3%
Revenue growth rate
-1.8%
Return on equity
21.2%
Net Margin
8.0%
Last Earnings Update
30 Sep 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How GSK makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:GS70 Revenue, expenses and earnings (GBP Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
31,311
2,511
10,839
6,042
30 Jun 24
31,446
4,033
9,284
6,049
31 Mar 24
30,740
4,484
9,070
5,956
31 Dec 23
30,328
4,928
9,156
5,823
30 Sep 23
29,652
6,078
8,965
5,580
30 Jun 23
29,334
5,373
8,767
5,436
31 Mar 23
29,085
4,455
8,460
5,282
31 Dec 22
29,324
4,461
8,179
5,153
30 Sep 22
29,024
3,387
7,803
4,905
30 Jun 22
27,822
3,505
7,429
4,741
31 Mar 22
26,731
4,013
7,104
4,691
31 Dec 21
24,696
3,316
6,784
4,627
30 Sep 21
26,359
3,567
7,436
4,640
30 Jun 21
28,378
3,934
8,285
4,566
31 Mar 21
30,164
4,983
9,176
4,622
31 Dec 20
24,354
4,873
7,041
4,397
30 Sep 20
34,259
6,371
10,719
4,537
30 Jun 20
34,998
6,679
11,085
4,648
31 Mar 20
35,183
5,380
10,993
4,519
31 Dec 19
33,754
4,645
10,962
4,405
30 Sep 19
33,052
4,561
10,103
4,266
30 Jun 19
31,759
4,427
9,575
4,065
31 Mar 19
31,260
3,904
9,488
3,887
31 Dec 18
30,821
3,623
9,500
3,799
30 Sep 18
30,263
1,862
9,234
3,755
30 Jun 18
30,014
1,656
9,185
3,696
31 Mar 18
30,024
1,035
9,143
3,890
31 Dec 17
30,186
1,532
9,424
3,925
30 Sep 17
30,133
2,335
9,303
3,886
30 Jun 17
29,832
1,931
9,260
3,863
31 Mar 17
29,044
1,676
9,017
3,604
31 Dec 16
27,889
912
8,852
3,550
30 Sep 16
26,589
301
8,553
3,370
30 Jun 16
25,174
31
8,025
3,226
31 Mar 16
24,530
615
8,097
3,163
31 Dec 15
23,923
8,422
9,232
3,560
30 Sep 15
23,823
9,809
7,810
3,218
30 Jun 15
23,342
9,672
7,425
3,227
31 Mar 15
23,015
10,177
7,261
3,258
31 Dec 14
23,006
2,756
8,246
3,450
30 Sep 14
23,726
4,184
7,209
3,333
30 Jun 14
24,590
4,752
7,673
3,359
31 Mar 14
25,647
5,143
7,820
3,478
31 Dec 13
26,505
5,436
8,480
3,923
Quality Earnings: GS70 has a large one-off loss of £3.0B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: GS70's current net profit margins (8%) are lower than last year (20.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GS70's earnings have declined by 5.2% per year over the past 5 years.
Accelerating Growth: GS70's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GS70 had negative earnings growth (-58.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: Whilst GS70's Return on Equity (21.17%) is high, this metric is skewed due to their high level of debt.